🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. TOOKAD 183 mg powder for solution for injection, PADELIPORFIN

    STEBA Biotech S.A

    Low Grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  2. TOPOTECAN , DOSTARLIMAB , BEVACIZUMAB , PACLITAXEL , NIRAPARIB , DOXORUBICIN , GEMCITABINE

    Fondazione Telethon ETS

    Recurrent ovarian, fallopian tube or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  3. TOPOTECAN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, GEMCITABINE HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  4. TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    GlaxoSmithKline

    Neoplasms, Lung

    phase 3 small molecule active

    1 trial

  5. TQJ230

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  6. TQJ230, INCLISIRAN, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  7. TQJ230, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Apheresis

    phase 3 small molecule active

    1 trial

  8. TRASTUZUMAB, Tislelizumab, Oxaliplatin 5 mg/ml concentrate for solution for infusion, LOPERAMIDE, JZP598, CAPECITABINE

    Jazz Pharmaceuticals Ireland Limited

    Gastroesophageal Adenocarcinoma (GEA)

    phase 3 small molecule active

    1 trial

  9. TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  10. TREPaed_10, TREPaed_5, TREPaed_0.5, TREPaed_2.5, TREPaed_1

    AOP Orphan Pharmaceuticals GmbH

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  11. TRIAMCINOLONE , VANCOMYCIN , CEFAZOLIN , BETAMETHASONE , OMEPRAZOLE , JNJ-74765340, JNJ-74765340, DEXAMETHASONE , CEFUROXIME

    Janssen-Cilag International N.V.

    X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene

    phase 3 small molecule active

    1 trial

  12. TROPICAMIDE, Vehicle for cenegermin drug product, COLIROFTA ANESTÉSICO DOBLE 1 MG/ML + 4 MG/ML COLIRIO EN SOLUCIÓN, OXERVATE 20 micrograms/ml eye drops, solution

    Dompe' Farmaceutici S.p.A.

    Persistent Corneal Epithelial Defect (PCED)

    phase 3 small molecule active

    1 trial

  13. TRUQAP 160 mg film-coated tablets, Fulvestrant Dr. Reddy’s 250 mg Solution For Injection in Pre-Filled Syringe, RLY-2608, Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe, Fulvestrant Dr. Reddys 250 mg solución inyectable en jeringa precargada EFG, TRUQAP 200 mg film-coated tablets

    Relay Therapeutics

    PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  14. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 3 small molecule active

    1 trial

  15. Tablet placebo for aficamten 5mg tablet, Aficamten

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  16. Tacrolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Transplantation

    phase 3 small molecule active

    1 trial

  17. Tacrolimus BID

    Teva Pharma GmbH

    Medication Adherence

    phase 3 small molecule active

    1 trial

  18. Tadalafil

    Eli Lilly and Company

    Hypertension, Pulmonary

    phase 3 small molecule completed

    1 trial

  19. Tadalafil

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    1 trial

  20. Taldefgrobep, Placebo Solution for injection in pre-filled syringe, Taldefgrobep

    Lacuna Pharma Pty Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  21. Tamiflu 75 mg hard capsules, DOLIPRANE 1000 mg, poudre pour solution buvable en sachet-dose

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  22. Tamoxifen

    International Peace Maternity and Child Health Hospital

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  23. Tapentadol IR 50 mg

    Janssen Cilag International NV

    Hallux Valgus

    phase 3 small molecule completed

    1 trial

  24. Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution

    AXIM BIOTECHNOLOGIES, INC.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources